Clinical Trials Logo

Tumors clinical trials

View clinical trials related to Tumors.

Filter by:

NCT ID: NCT00171587 Completed - Neoplasm Metastasis Clinical Trials

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

Start date: May 2002
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to assess the safety, tolerability, dose limiting toxicity, and maximum tolerated dose of vatalanib administered orally once daily in combination with capecitabine in patients with advanced cancer. The study is also designed to determine the effect of vatalanib on the pharmacokinetics of capecitabine and the effect of capecitabine on the pharmacokinetics of vatalanib, and to describe the anti-tumor activity of this combination regimen.

NCT ID: NCT00129337 Completed - Tumors Clinical Trials

Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there. The effect of bavituximab on tumor responses will also be examined.

NCT ID: NCT00129207 Completed - Tumors Clinical Trials

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate how ketoconazole (Nizoral) affects the pharmacokinetics (how the study drug is affected by the body and broken down) and pharmacodynamics (how the study drug acts on the body) of the active ingredient in the study drug Velcade (bortezomib).

NCT ID: NCT00127829 Completed - Tumors Clinical Trials

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

AGUS
Start date: July 2005
Phase: Phase 1
Study type: Interventional

This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.

NCT ID: NCT00127127 Completed - Tumors Clinical Trials

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

Start date: June 10, 2005
Phase: Phase 1
Study type: Interventional

The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.

NCT ID: NCT00113113 Completed - Tumors Clinical Trials

Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Start date: August 2001
Phase: Phase 1
Study type: Interventional

Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.

NCT ID: NCT00102830 Completed - Tumors Clinical Trials

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.

NCT ID: NCT00093873 Completed - Tumors Clinical Trials

Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

NCT ID: NCT00091806 Completed - Solid Tumors Clinical Trials

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of two dose schedules of panitumumab in subjects with advanced solid tumors.

NCT ID: NCT00060645 Completed - Multiple Myeloma Clinical Trials

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Start date: May 2003
Phase: Phase 1
Study type: Interventional

Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.